Evidence map›Paper›PMID 32623595›Full record

ArticleJournal of neurology2020

Treatment of MOG antibody associated disorders: results of an international survey.

D H Whittam, V Karthikeayan, E Gibbons, R Kneen, S Chandratre, O Ciccarelli, Y Hacohen, J de Seze, K Deiva, R Q Hintzen and 54 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Stem Cell-Based Therapies for Central Nervous System Demyelinating Diseases: Clinical Evidence, Therapeutic Niches, and Translational Boundaries.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Validation of the MOG-AR Score: A Retrospective Multicenter Study.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Article
  9. Article
  10. Review
  11. Neuroglial markers of damage in autoimmune neurology.Therapeutic advances in neurological disorders · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. MOGJournal of neuroinflammation · 2025
    Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

64 authors at 20 institutions in 20 countries.

D H WhittamDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK. daniel.whittam@nhs.net.ORCID http://orcid.org/0000-0002-9430-8190
V KarthikeayanDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
E GibbonsDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
R KneenDepartment of Paediatric Neurology, Alder Hey Children's Hospital, Liverpool, UK.
S ChandratreNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.
O CiccarelliQueen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK.
Y HacohenQueen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK.
J de SezeDepartment of Neurology and Clinical Investigation Center, CHU de Strasbourg, Hôpital de Hautepiere, Strasbourg, France.
K DeivaDepartment of Paediatric Neurology, CHU Paris-Sud, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
R Q HintzenDepartment of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands.
B WildemannMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
S JariusMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
I KleiterDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
K RostasyDepartment of Paediatric Neurology, Children's Hospital Datteln, Witten/Herdrecke University, Datteln, Germany.
P HuppkeDepartment of Paediatrics and Paediatric Neurology, University Medical Center Göttingen, Georg-August University, Göttingen, Germany.
B HemmerDepartment of Neurology, School of Medicine, Technical University of Munich, Munich, Germany.
F PaulNeuroCure Clinical Research Center, and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
O AktasDepartment of Neurology, Heinrich-Heine-Universität Düsseldorf, 40225, Düsseldorf, Germany.
A K PröbstelDepartment of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
G ArrambideServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
M TintoreServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
M P AmatoDepartment NEUROFARBA, Neurosciences Section, University of Florence, Florence, Italy.
M NosadiniPaediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
M M MancardiDepartment of Medical and Surgical Neurosciences and Rehabilitation, IRCCS Giannina Gaslini Institute, Genoa, Italy.
M CapobiancoDepartment of Neurology and Regional Multiple Sclerosis Centre, University Hospital San Luigi Gonzaga, Orbassano, Italy.
Z IllesDepartment of Neurology, Odense University Hospital, Odense, Denmark.
A SivaDepartment of Neurology, Istanbul University Cerrahpaşa School of Medicine, Istanbul, Turkey.
A AltintasDepartment of Neurology, School of Medicine, Koc University, Istanbul, Turkey.
G Akman-DemirDepartment of Neurology, Bilim University, Istanbul, Turkey.
L PanditDepartment of Neurology, Nitte University, Mangalore, Karnataka, India.
M ApiwattankulNeuroimmunology Unit, Department of Neurology, Prasat Neurological Institute, Ministry of Public Health, Bangkok, Thailand.
J Y HorDepartment of Neurology, Penang General Hospital, Penang, Malaysia.
S ViswanathanDepartment of Neurology, Kuala Lumpur Hospital, Ministry of Health of Malaysia, Kuala Lumpur, Malaysia.
W QiuDepartment of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
H J KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
I NakashimaDepartment of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
K FujiharaDepartment of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine and Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan.
S RamanathanSydney Medical School, University of Sydney, Sydney, NSW, Australia.
R C DaleSydney Medical School, University of Sydney, Sydney, NSW, Australia.
M BoggildDepartment of Neurology, Townsville Hospital, Townsville, QLD, Australia.
S BroadleySchool of Medicine, Gold Coast Campus, Griffith University, Mount Gravatt, QLD, Australia.
M A Lana-PeixotoCIEM MS Research Center, Federal University of Minas Gerais Medical School, Belo Horizonte, MG, Brazil.
D K SatoInstituto do Cérebro do Rio Grande do Sul (InsCer), Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
S TenembaumDepartment of Neurology, National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina.
P CabreDepartment of Neurology, Pierre Zobda Quitman Hospital, Fort-de-France, France.
D M WingerchukDepartment of Neurology, Mayo Clinic, Scottsdale, AZ, USA.
B G WeinshenkerDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
B GreenbergDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
M MatielloDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
E C KlawiterDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
J L BennettDepartment of Ophthalmology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA.
A I WallachDepartment of Neurology, NYU School of Medicine, New York, NY, USA.
I KisterDepartment of Neurology, NYU School of Medicine, New York, NY, USA.
B L BanwellDepartment of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
A TraboulseeDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
D PohlDivision of Neurology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
J PalaceNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.
M I LeiteNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.
M LevyDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
R MarignierService de Neurologie, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France.
T SolomonDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
M LimChildren's Neuroscience, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
S HudaDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
A JacobDepartment of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
University of Liverpool · GBHarvard University · USJohn Radcliffe Hospital · GBHeidelberg University · DEMayo Clinic in Arizona · USNew York University · USThe University of Sydney · AUUniversitat Autònoma de Barcelona · ESBicêtre Hospital · FRChildren's Hospital of Eastern Ontario · CAChildren's Hospital of Philadelphia · USDon Carlo Gnocchi Foundation · ITErasmus MC · NLFukushima Medical University · JPGarrahan Hospital · ARGreat Ormond Street Hospital · GBGriffith University · AUHeinrich Heine University Düsseldorf · DEHôpital d'Hautepierre · FRHospices Civils de Lyon · FR

Funding

Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis OpticaR01EY022936 · NEI · UNIVERSITY OF COLORADO DENVER · PI BENNETT, JEFFREY L · 2013 to 2022
$3.8M
NEI NIH HHS R01 EY022936
6 · The paper itself

Abstract

introductionWhile monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed.

objectiveTo survey the current global clinical practice of clinicians treating MOGAD.

methodNeurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019).

resultsFifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT.

conclusionCurrent treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.

Indexed as

AutoantibodiesImmunoglobulins, IntravenousAdultChildHumansMyelin-Oligodendrocyte GlycoproteinPlasmapheresisSurveys and QuestionnairesAutoantibodiesImmunoglobulins, IntravenousMyelin-Oligodendrocyte GlycoproteinMOGMOGADMyelin oligodendrocyte glycoproteinSurvey

Identifiers

PMID32623595
PMCPMC7954658
OpenAlexW3034500157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.